Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors have been reported in several Daewoong Pharmaceutical Co. Ltd. patents. They are described as potentially useful for the treatment of cancer and autoimmune diseases.
The University of Washington has divulged antibody-drug conjugates (ADCs) comprising an antibody targeting HER2 (erbB2) linked to monomethyl auristatin E (MMAE) through a linker. They are described as useful for the treatment of cancer.
Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.
The University of Michigan has disclosed pyrrolo[1,2-a]-azocine analogues acting as as inhibitor of apoptosis proteins (IAP) inhibitors. As such, they are reported to be potentially useful for the treatment of AIDS, cancer, infections, psoriasis, multiple sclerosis, vascular disorders, inflammatory disorders and autoimmune diseases.
Shenzhen Newrosetta Biosciences Co. Ltd. has divulged benzodiazepine derivatives acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia.
Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. has discovered somatostatin SST2 receptor agonists described as potentially useful for the treatment of acute pancreatitis and peptic ulcer bleeding.
Negio Therapeutics NV has disclosed guanfacine derivatives acting as α2-adrenoceptor agonists. They are reported to be useful for the treatment of cancer.
Chong Kun Dang Pharmaceutical Corp. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of cardiovascular, endocrine, immunological, psychiatric, renal, inflammatory disorders, metabolic diseases and neurodegeneration.
Zincure Corp. has discovered matrix metalloproteinase-9 (MMP-9, gelatinase B) inhibitors reported to be useful for the treatment of epilepsy, stroke, multiple sclerosis, hypoglycemic encephalopathy and traumatic brain injury.
RSS